Research
Hormonal
Co-agonism of the glucagon and GLP-1 receptors improves glycemia in people with diabetes and obesity.
Practitioners may consider glucagon and GLP-1 receptor co-agonists as a treatment option for improving glycemia.
StrongSupportsmedium confidence
Co-agonism of the glucagon and glucagon-like peptide-1 (GLP-1) receptors has emerged as a promising strategy to improve glycemia in people with diabetes and obesity.
Why this rating
The claim is based on emerging strategies supported by research.
Source
Glucagon-based therapy for people with diabetes and obesity: What is the sweet spot?
Emma Rose McGlone et al. · Peptides · 2024
DOI 10.1016/j.peptides.2024.171219
otherCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →